Eli Lilly and Company Common Stock (LLY) stock analysis
LLY · Eli Lilly and Company Common Stock
Latest recorded price: USD 1,431.67
Model-estimated fair value: USD 602.51. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - General
At $1,431.67, LLY trades 137.6% above the model's base-case value of $602.51. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $440.76 in the conservative case and $797.61 in the optimistic case, with a valuation confidence score of 65/100. Fiscal 2025 figures: revenue growth 31.7%, free cash flow margin 13.8%, ROIC 28.6%. The model does not flag any risk signals for this company.